A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The study schedule is comprised of a 14-day Screening Period, a treatment period and an
observation period. All eligible subjects will be randomized into one of 3 treatment groups
(1 of 2 dose levels or matched placebo). Study drug CR845 will be administered intravenously
prior to surgery, and at specific time intervals post surgery. Additional rescue pain and
anti-nausea medication will be made available. Post surgical changes in pain intensity,
nausea and vomiting will be assessed.